Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

The effects of dopamine D1 and D2 receptor antagonists on the rewarding effects of δ1 and δ2 opioid receptor agonists in mice

  • 50 Accesses

  • 27 Citations


The effects of the dopamin D1 antagonist SCH23390 and the D2 antagonist sulpiride on the rewarding effects of δ opioid receptor agonists were examined in mice. Both [d-Pen2, Pen5]enkephalin (DPDPE, 1–15 nmol, ICV), a selective δ1 opioid receptor agonist, and [d-Ala2]deltorphin II (DELT, 0.5–5 nmol, ICV), a selective δ2 opioid receptor agonist, produced a dose-dependent place preference in mice. The DPDPE (15 nmol, ICV)-induced place preference was abolished by BNTX (0.5 mg/kg, SC), a δ1 opioid receptor antagonist, but not by NTB (0.5 mg/kg, SC), a δ2 opioid receptor antagonist. In contrast, the DELT (5 nmol, ICV)-induced place preference was antagonized by NTB, but not BNTX. Pretreatment with SCH23390 (3 µg/kg, SC) abolished the DPDPE-induced place preference, but not affect the DELT-induced place preference. Moreover, pretreatment with sulpiride (40 mg/kg, SC) did not modify the place preference induced by DPDPE or DELT. In the present study, we found that the activation of both central δ1 and δ2 opioid receptors produced rewarding effects. Furthermore, these results suggest that the rewarding effects of δ1 opioid receptor agonist may be produced through activation of the central dopaminergic system, especially dopamine D1 receptors, whereas the rewarding effects of δ2 opioid receptor agonists may be produced by some other mechanism(s).

This is a preview of subscription content, log in to check access.


  1. Abdelhamid EM, Sultana M, Portoghese PS, Takemori AE (1991) Selective blockade of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J Pharmacol Exp Ther 258:299–303

  2. Bals-Kubik R, Shippenberg TS, Herz A (1990) Involvement of central μ and δ opioid receptors in mediating the reinforcing effects of β-endorphin in the rat. Eur J Pharmacol 175:63–69

  3. Bozarth MA (1987) Neuroanatomical boundaries of the rewardrelevant opiate-receptor field in the ventral tegmental area as mapped by the conditioned place preference method in rats. Brain Res 414:77–84

  4. Bozarth MA, Wise RA (1981) Heroin reward is dependent on a dopaminergic substrate. Life Sci 29:1881–1886

  5. Broekkamp CL, Phillips AG, Cools AR (1979a) Stimlant effects of enkephalin microinjection into the dopaminergic A10 area. Nature 278:560–562

  6. Broekkamp CL, Phillips AG, Cools AR (1979b) Facilitation of self-administration behavior following intracerebral microinjections of opioids into the ventral tegmental area. Pharmacol Biochem Behav 11:289–295

  7. Carr GD, Fibiger HC, Phillips AG (1989) Conditioned place preference as a measure of drug reward. In: Liebman JM, Cooper SJ (eds) The neuropharmacological basis of reward. Oxford University Press, New York, pp 264–319

  8. Chang K-J, Cuatrecasas P (1979) Multiple opiate receptors: enkephalins and morphine bind to receptors of different specificity. J Biol Chem 254:2610–2618

  9. Comer SD, McNutt RW, Chang K-J, De Costa BR, Mosberg HI, Woods JH (1983) Discriminative stimulus effects of BW373U86: a nonpeptide ligand with selectivity for delta opioid receptors. J Pharmacol Exp Ther 267:866–874

  10. Costall B, Naylor RJ (1976) Antagonism of the hyperactivity induced by dopamine applied intracerebrally to the nucleus accumbens septi by typical neuroleptics and by clozapine, sulpiride and thioridazine. Eur J Pharmacol 35:161–168

  11. Di Chiara G, Imperato A (1988) Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 244:1067–1080

  12. Di Chiara G, North RA (1992) Neurobiology of opiate abuse. Trends Pharmacol Sci 13:185–193

  13. Ettenberg A, Pettit HO, Bloom FE, Koob GF (1982) Heroin and cocaine intravenous self-administration in rats: mediation by separate neural systems. Psychopharmacology 78:204–209

  14. Funada M, Suzuki T, Narita M, Misawa M, Hiroshi N (1993) Blockade of morphine reward through the activation ofk-opioid receptors in mice. Neuropharmacology 32:1315–1323

  15. Haley TJ, McCormick WG (1957) Pharmacological effects produced by intracerebral injections of drugs in the conscious mouse. Br J Pharmacol 12:12–15

  16. Hong JS, Yang HYT, Fratta W, Costa E (1978) Rat striatal methionine-enkephalin content after chronic treatment with cataleptogenic and noncataleptogenic antischizophrenic drugs. J Pharmacol Exp Ther 205:141–147

  17. Hong JS, Yang HYT, Gillin JC, Digiulio AM, Fratta W, Costa E (1979) Chronic treatment with haloperidol accelerates biosynthesis of enkephalin in rat striatum. Brain Res 160:192–195

  18. Jiang Q, Takemori AE, Sultana M, Portoghese PS, Bowen WD, Mosberg HI, Porreca F (1991) Differential antagonism of opioid delta antinociception by [d-Ala2, Leu5, Cys6]enkephalin and naltrindole 5′-isothiocyanate: evidence for delta receptor subtypes. J Pharmacol Exp Ther 257:1069–1075

  19. Joyce EM, Iversen SD (1979) The effect of morphine applied locally to mesencephalic dopamine cell bodies on spontaneous motor activity in the rat. Neurosci Lett 14:207–212

  20. Kalivas PW, Bronson M (1985) Mesolimbic dopamine lesions produce an augmented behavioral response to enkephalin. Neuropharmacology 24:931–936

  21. Kalivas PW, Widerlov E, Stanley D, Breese G, Prange AJ Jr (1983) Enkephalin action on the mesolimbic system: a dopamine-dependent and a dopamine-independent increase in locomotor activity. J Pharmacol Exp Ther 227:229–237

  22. Kelley AE, Stinus L, Iversen SD (1980) Interactions between,d-ala-met-enkephalin, A10 dopaminergic neurons, and spontaneous behavior in the rat. Behav Brain Res 1:3–24

  23. Koob GF (1992) Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 13:177–184

  24. Longoni R, Spina L, Mulas A, Carboni E, Garau L, Melchiorri P, Di Chiara G (1991) (D-Ala2)deltorphin II: D1-dependet stereotypies and stimulation of dopamine release in the nucleus accumbens. J Neurosci 11:1565–1576

  25. Lord JAH, Waterfield AA, Hughes J, Kosterlitz HW (1977) Endogenous opioid peptides: multiple agonists and receptors. Nature (London) 267:495–499

  26. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ (1988) Anatomy of CNS opioid receptors. Trends Neurosci 11:308–314

  27. Mattia A, Vanderah T, Mosberg HI, Porreca F (1991) Lack of antinociceptive cross-tolerance between (d-Pen2,d-Pen5] enkephalin and [d-Ala2]deltorphin II in mice: evidence for delta receptor subtypes. J Pharmacol Exp Ther 258:583–587

  28. Miyamoto Y, Portoghese PS, Takemori AE (1993a) Involvement of delta2 opioid receptors in the development of morphine dependence in mice. J Pharmacol Exp Ther 264:1141–1145

  29. Miyamoto Y, Portoghese PS, Takemori AE (1993b) Involvement of δ2 opioid receptors in acute dependence on morphine in mice. J Pharmacol Exp Ther 265:1325–1327

  30. Mizuchi A, Kitagawa N, Miyachi T (1983) Regional distribution of sultopride and sulpiride in rat brain measured by radioimmunoassay. Psychopharmacology 81:195–198

  31. Mognan J, Paterson SJ, Tavani A, Kosterlitz HW (1982) The bind spectrum of narcotic analgesic drugs with different agonist and antagonist properties. Naunyn-Schmiedeberg's Arch Pharmacol 319:197–205

  32. Narita M, Suzuki T, Funada M, Misawa M, Nagase H (1993) Involvement of δ-opioid receptors in the effects of morphine on locomotor activity and the mesolimbic dopaminergic system in mice. Psychopharmacology 111:423–426

  33. Pert A, Sivit C (1977) Neuroanatomical focus for morphine and enkephalin-induced hypermotility. Nature 265:645–647

  34. Phillips AG, LePiane FG (1980) Reinforcing effects of morphine microinjection into the ventral tegmental area. Pharmacol Biochem Behav 12:965–968

  35. Phillips AG, LePiane (1982) Reward produced by microinjection of (d-ala-2) met5-enkephalinamide into the ventral tegmetnal area. Behav Brain Res 5:225–229

  36. Portoghese PS, Sultana M, Takemori AE (1988) Naltrindole, a highly selective and potent non-peptide δ opioid receptor antagonist. Eur J Pharmacol 146:185–186

  37. Portoghese PS, Sultana M, Takemori AE (1990) Design of peptidomimetic δ opioid antagonists using the message-address concept. J Med Chem 33:1714–1720

  38. Portoghese PS, Nagase H, MaloneyHuss KE, Lin C-E, Takemori AE (1991) Role of spacer and address components in peptidomimetic δ opioid receptor antagonists related to naltrindole. J Med Chem 34:1715–1720

  39. Portoghese PS, Sultana M, Nagase H, Takemori AE (1992) A highly selective δ1-opioid receptor antagonist: 7-benzylidenenaltrexone. Eur J Pharmacol 218:195–196

  40. Sabol SL, Yoshikama K, Hong JS (1983) Regulation of methionine-enkephalin precursor messenger RNA in rat striatum by haloperidol and lithium. Biochem Biophy Res Commun 113:391–399

  41. Shippenberg TS (1993) Motivational effects of opioids. In: Herz A (ed) Opioids II. Springer, Berlin, pp 633–650

  42. Shippenberg TS, Herz A (1988) Motivational effects of opioids: Influence of D-1 versus D-2 receptor antagonists. Eur J Pharmacol 151:233–242

  43. Shippenberg TS, Bals-Kubik R, Herz A (1987) Motivational properties of opioids: evidence that an activation of δ-receptors mediates reinforcement processes. Brain Res 436:234–239

  44. Sofuoglu M, Portoghese PS, Takemori AE (1991) Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: evidence for delta opioid receptor subtypes. J Pharmacol Exp Ther 257:676–680

  45. Sofuoglu M, Portoghese PS, Takemori AE (1993) 7-Benzylidenenaltrexone (BNTX): a selective δ1 opioid receptor antagonist in the mouse spinal cord. Life Sci 52:769–775

  46. Spanagel R, Herz A, Shippenberg TS (1990) The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J Neurochem 55:1734–1740

  47. Spyraki C, Fibiger NC, Phillips AG (1983) Attenuation of heroin reward in rats by disruption of mesolimbic dopamine system. Psychopharmacology 79:278–283

  48. Stinus L, Koob GF, Ling N, Bloom FE, Le Moal M (1980) Locomotor activation induced by infusion of endorphins into the ventral tegmental area: evidence for opiate-dopamine interactions. Proc Natl Acad Sci USA 77:2323–2327

  49. Stinus L, Nadaud D, Jauregui J, Kelly AE (1986) Chronic treatment with five different neuroleptics elicits behavioral supersensitivity to opiate infusion into the nicleus accumbens. Biol Psychiatry 21:34–48

  50. Stinus L, Nadaud D, Deminiere JM, Jauregui J, Hand TT, Le Moal M (1989) Chronic flupentixol treatment potentiates the reinforcing properties of systemic heroin administration. Biol Psychiatry 26:363–371

  51. Suzuki T, Masukawa Y, Misawa M (1990) Drug interactions in the reinforcing effects of over-the-counter cough syrups. Psychopharmacology 102:438–442

  52. Suzuki T, Funada M, Narita M, Misawa M, Nagase H (1991) Pertussis toxin abolishes μ- and δ-opioid agonist-induced place preference. Eur J Pharmacol 205:85–88

  53. Suzuki T, Funada M, Narita M, Misawa M, Nagase H (1993) Morphine-induced place preference in the CXBK mouse: characteristics of μ opioid receptor subtypes. Brain Res 602:45–52

  54. Suzuki T, Yoshiike M, Mizoguchi H, Kamei J, Misawa M, Nagase H (1994) Blockade of δ-opioid receptors prevents morphineinduced place preference in mice. Jpn J Pharmacol 66:131–137

  55. Suzuki T, Takamori K, Misawa M, Onodera K (1995) Effects of the histaminergic system on the morphine-induced conditioned place preference in mice. Brain Res 675:195–202

  56. Takemori AE, Portoghese PS (1987) Evidence for the interaction of morphine with kappa and delta opioid receptors to induce analgesia in β-funaltrexamine-treated mice. J Pharmacol Exp Ther 243:91–94

  57. Thal LH, Sharpless NS, Hirschhorn ID, Horowitz SG, Makman MH (1983) Striatal metenkephalin concentration increases following nigro-striatal denervation. Biochem Pharmacol 32:3297–3301

Download references

Author information

Correspondence to T. Suzuki.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Suzuki, T., Tsuji, M., Mori, T. et al. The effects of dopamine D1 and D2 receptor antagonists on the rewarding effects of δ1 and δ2 opioid receptor agonists in mice. Psychopharmacology 124, 211–218 (1996). https://doi.org/10.1007/BF02246659

Download citation

Key words

  • Opioid receptors
  • Conditioned place preference
  • Dopamine D1 and D2 receptors
  • BNTX
  • NTB
  • Reinforcement